Virgin olive oil phenolic compounds modulate the HDL lipidome in hypercholesterolaemic subjects: a lipidomic analysis of the VOHF study

The lipidomic analysis of high-density lipoprotein (HDL) could be useful to identify new biomarkers of HDL function. Methods and results: A randomized, controlled, double-blind, crossover trial (33 hypercholesterolaemic subjects) is performed with a control virgin olive oil (VOO), VOO enriched with its own phenolic compounds (FVOO), or VOO enriched with additional phenolic compounds from thyme (FVOOT) for 3 weeks. HDL lipidomic analyses are performed using the Lipidyzer platform. VOO and FVOO intake increase monounsaturated-fatty acids (FAs) and decrease saturated and polyunsaturated FAs in triacylglyceride (TAG) species, among others species. In contrast, FVOOT intake does not induce these FAs changes. The decrease in TAG52:3(FA16:0) after VOO intake and the decrease in TAG52:5(FA18:2) after FVOO intake are inversely associated with changes in HDL resistance to oxidation. After FVOO intake, the decrease in TAG54:6(FA18:2) in HDL is inversely associated with changes in HDL cholesterol efflux capacity. Conclusion: VOO and FVOO consumption has an impact on the HDL lipidome, in particular TAG species. Although TAGs are minor components of HDL mass, the observed changes in TAG modulated HDL functionality towards a cardioprotective mode. The assessment of the HDL lipidome is a valuable approach to identify and characterize new biomarkers of HDL function.

The VOHF project (AGL2009-13517-457 C03-01) and the AppleCOR Project (AGL2016-76943-C2) were made possible with the support of the Ministerio de Economía, Indústria y Competitividad, the Agencia Estatal de Investigación, and the European Regional Development Fund. U.C. has a Pla Estratègic de Recerca i Innovació en Salut (PERIS) postdoctoral grant (no. SLT002/16/00239; Catalunya, Spain) from the Generalitat de Catalunya. A.P. has a Torres Quevedo postdoctoral grant with the Subprograma Estatal de Incorporación, Plan Estatal de Investigación Científica Técnica y de Innovación. M.F. has a Sara Borrell postdoctoral contract (CD17/00233 to M.F.-St.Pau). O.C. has a JR17/00022 contract from Instituto de Salud Carlos III. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a project of Instituto de Salud Carlos III (Madrid, Spain). The NFOC-Salut group is a consolidated research group of the Generalitat de Catalunya, Spain (reference no. 2017 SGR 522).